{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T12:40:03Z","timestamp":1737204003314,"version":"3.33.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,18]]},"DOI":"10.7759\/cureus.77616","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T12:02:11Z","timestamp":1737201731000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Outcomes of Clostridioides difficile Infection in Cancer Patients From a Tertiary Care Hospital"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Arslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Usman","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umer","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baryah","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahel","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Summiya","family":"Nizamuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5937\/scriptamed54-42419","article-title":"Epidemiological and clinical characteristics of patients with healthcare: associated Clostridioides difficile infection before and during the COVID-19 pandemic","volume":"54","author":"Kne\u017eevi\u0107 D","year":"2023","unstructured":"Kne\u017eevi\u0107 D, Jovi\u0107 D, Petkovi\u0107 M. Epidemiological and clinical characteristics of patients with healthcare: associated Clostridioides difficile infection before and during the COVID-19 pandemic. Scr Med. 2023, 54:19-27. 10.5937\/scriptamed54-42419","journal-title":"Scr Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219579.g001","article-title":"Correction: evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital","volume":"9","author":"Sheth PM","year":"2019","unstructured":"Sheth PM, Douchant K, Uyanwune Y, et al.. Correction: evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital. PLoS One. 2019, 9:e0219579. 10.1371\/journal.pone.0219579.g001","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2021.02.007","article-title":"Clinical characteristics associated with the severity of Clostridium [Clostridioides] difficile infection in a tertiary teaching hospital from Mexico","volume":"45","author":"Tijerina-Rodr\u00edguez L","year":"2022","unstructured":"Tijerina-Rodr\u00edguez L, Garza-Gonz\u00e1lez E, Mart\u00ednez-Mel\u00e9ndez A, et al.. Clinical characteristics associated with the severity of Clostridium [Clostridioides] difficile infection in a tertiary teaching hospital from Mexico. Biomed J. 2022, 45:200-5. 10.1016\/j.bj.2021.02.007","journal-title":"Biomed J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1184","article-title":"Clostridioides difficile infection in cancer and immunocompromised patients: relevance of a two-step diagnostic algorithm and infecting ribotypes on clinical outcomes","volume":"72","author":"Yepez Guevara EA","year":"2021","unstructured":"Yepez Guevara EA, Aitken SL, Olvera AV, et al.. Clostridioides difficile infection in cancer and immunocompromised patients: relevance of a two-step diagnostic algorithm and infecting ribotypes on clinical outcomes. Clin Infect Dis. 2021, 72:e460-5. 10.1093\/cid\/ciaa1184","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2020.277","article-title":"Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: a systematic review and meta-analysis","volume":"41","author":"Babar S","year":"2020","unstructured":"Babar S, El Kurdi B, El Iskandarani M, et al.. Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2020, 41:1302-9. 10.1017\/ice.2020.277","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002574","article-title":"Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study","volume":"29","author":"Milenkovi\u0107 B","year":"2022","unstructured":"Milenkovi\u0107 B, \u0160uljagi\u0107 V, Peri\u0107 A, et al.. Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. Eur J Hosp Pharm. 2022, 29:e15-22. 10.1136\/ejhpharm-2020-002574","journal-title":"Eur J Hosp Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13020144","article-title":"A real-world study on the clinical characteristics, outcomes, and relationship between antibiotic exposure and Clostridioides difficile infection","volume":"13","author":"Vintila BI","year":"2024","unstructured":"Vintila BI, Arseniu AM, Morgovan C, et al.. A real-world study on the clinical characteristics, outcomes, and relationship between antibiotic exposure and Clostridioides difficile infection. Antibiotics (Basel). 2024, 13:144. 10.3390\/antibiotics13020144","journal-title":"Antibiotics (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy845","article-title":"Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention","volume":"68","author":"Revolinski SL","year":"2019","unstructured":"Revolinski SL, Munoz-Price LS. Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention. Clin Infect Dis. 2019, 68:2144-53. 10.1093\/cid\/ciy845","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.12251","article-title":"Treatment of Clostridioides difficile infection","volume":"328","author":"Sehgal K","year":"2022","unstructured":"Sehgal K, Cifu AS, Khanna S. Treatment of Clostridioides difficile infection. JAMA. 2022, 328:881-2. 10.1001\/jama.2022.12251","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4081\/itjm.2024.1666","article-title":"Clostridioides difficile infection in hospital and community settings: summary document of a multidisciplinary group","volume":"18","author":"Danise A","year":"2024","unstructured":"Danise A, Furfaro F, Gattuso G, Liberato NL, Mandelli C, Mazzola G, Osnaghi B. Clostridioides difficile infection in hospital and community settings: summary document of a multidisciplinary group. Ital J Med. 2024, 18:10.4081\/itjm.2024.1666","journal-title":"Ital J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa484","article-title":"Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America clinical practice guidelines on the treatment of Clostridium difficile infections in the United States","volume":"72","author":"Clancy CJ","year":"2021","unstructured":"Clancy CJ, Buehrle D, Vu M, Wagener MM, Nguyen MH. Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America clinical practice guidelines on the treatment of Clostridium difficile infections in the United States. Clin Infect Dis. 2021, 72:1944-9. 10.1093\/cid\/ciaa484","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson S","year":"2021","unstructured":"Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021, 73:e1029-44. 10.1093\/cid\/ciab549","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46574","article-title":"Clostridioides difficile infection in the neurorehabilitation setting: importance of a multidisciplinary approach and impact of the fecal microbiota transplantation","volume":"15","author":"Secondo D","year":"2023","unstructured":"Secondo D, Massaro D, Verrienti G, Perri F, Biscaglia G. Clostridioides difficile infection in the neurorehabilitation setting: importance of a multidisciplinary approach and impact of the fecal microbiota transplantation. Cureus. 2023, 15:e46574. 10.7759\/cureus.46574","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.08.006","article-title":"Update on treatment of Clostridioides difficile infection","volume":"95","author":"Cho JM","year":"2020","unstructured":"Cho JM, Pardi DS, Khanna S. Update on treatment of Clostridioides difficile infection. Mayo Clin Proc. 2020, 95:758-69. 10.1016\/j.mayocp.2019.08.006","journal-title":"Mayo Clin Proc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00293","article-title":"Risk factors for primary Clostridium difficile infection; results from the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID)","volume":"8","author":"Davies K","year":"2020","unstructured":"Davies K, Lawrence J, Berry C, et al.. Risk factors for primary Clostridium difficile infection; results from the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Front Public Health. 2020, 8:293. 10.3389\/fpubh.2020.00293","journal-title":"Front Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.685320","article-title":"Prospective multicenter study of chemotherapy-induced Clostridium (Clostridioides) difficile infection in patients with lung cancer: North Japan Lung Cancer Study Group Trial 1204","volume":"11","author":"Toi Y","year":"2021","unstructured":"Toi Y, Kobayashi T, Harada T, Nakagawa T, Mori Y, Kuda T, Sugawara S. Prospective multicenter study of chemotherapy-induced Clostridium (Clostridioides) difficile infection in patients with lung cancer: North Japan Lung Cancer Study Group Trial 1204. Front Oncol. 2021, 11:685320. 10.3389\/fonc.2021.685320","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2553-z","article-title":"Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals","volume":"17","author":"Delgado A","year":"2017","unstructured":"Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals. BMC Infect Dis. 2017, 17:448. 10.1186\/s12879-017-2553-z","journal-title":"BMC Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07651-4","article-title":"Performance of Clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer","volume":"31","author":"De-la-Rosa-Martinez D","year":"2023","unstructured":"De-la-Rosa-Martinez D, Zinser-Peniche P, Martin-Onraet A, Rivera-Buend\u00eda F, Vilar-Compte D. Performance of Clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer. Support Care Cancer. 2023, 31:187. 10.1007\/s00520-023-07651-4","journal-title":"Support Care Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.07.008","article-title":"Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study","volume":"29","author":"Boven A","year":"2023","unstructured":"Boven A, Vlieghe E, Engstrand L, Andersson FL, Callens S, Simin J, Brusselaers N. Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study. Clin Microbiol Infect. 2023, 29:1424-30. 10.1016\/j.cmi.2023.07.008","journal-title":"Clin Microbiol Infect"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.900681","article-title":"Risk factors of severe Clostridioides difficile infection; sequential organ failure assessment score, antibiotics, and ribotypes","volume":"13","author":"Choi MH","year":"2022","unstructured":"Choi MH, Kim D, Jeong SH, Lee HM, Kim H. Risk factors of severe Clostridioides difficile infection; sequential organ failure assessment score, antibiotics, and ribotypes. Front Microbiol. 2022, 13:900681. 10.3389\/fmicb.2022.900681","journal-title":"Front Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086\/669081","article-title":"Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy","volume":"34","author":"Wang MS","year":"2013","unstructured":"Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2013, 34:127-32. 10.1086\/669081","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15102","article-title":"Systematic review on the definition and predictors of severe Clostridiodes difficile infection","volume":"36","author":"Zhang VR","year":"2021","unstructured":"Zhang VR, Woo AS, Scaduto C, et al.. Systematic review on the definition and predictors of severe Clostridiodes difficile infection. J Gastroenterol Hepatol. 2021, 36:89-104. 10.1111\/jgh.15102","journal-title":"J Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa476","article-title":"Assessment of kidney injury as a severity criteria for Clostridioides difficile infection","volume":"7","author":"Carlson TJ","year":"2020","unstructured":"Carlson TJ, Gonzales-Luna AJ, Nebo K, et al.. Assessment of kidney injury as a severity criteria for Clostridioides difficile infection. Open Forum Infect Dis. 2020, 7:ofaa476. 10.1093\/ofid\/ofaa476","journal-title":"Open Forum Infect Dis"},{"key":"ref24","unstructured":"Clostridial difficile and leukocytosis. (2024). https.\/\/www.thebloodproject.com\/clostridial-difficile-and-leukocytosis\/."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1188\/19.CJON.165-171","article-title":"Clostridium difficile infection: the effects of acid suppression therapy in patients with cancer","volume":"23","author":"Lan H","year":"2019","unstructured":"Lan H. Clostridium difficile infection: the effects of acid suppression therapy in patients with cancer. Clin J Oncol Nurs. 2019, 23:165-71. 10.1188\/19.CJON.165-171","journal-title":"Clin J Oncol Nurs"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e08450","article-title":"To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors","volume":"7","author":"Sahu KK","year":"2021","unstructured":"Sahu KK, Mishra AK, Jindal V, Siddiqui AD, George SV. To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors. Heliyon. 2021, 7:e08450. 10.1016\/j.heliyon.2021.e08450","journal-title":"Heliyon"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S333985","article-title":"Characteristics, risk factors, and prevalence of Clostridioides difficile among hospitalized patients in a tertiary care hospital in Palestine","volume":"14","author":"Abukhalil AD","year":"2021","unstructured":"Abukhalil AD, AbuKhdeir L, Hamed M, Al Shami N, Naseef HA, Aiesh BM, Sabateen A. Characteristics, risk factors, and prevalence of Clostridioides difficile among hospitalized patients in a tertiary care hospital in Palestine. Infect Drug Resist. 2021, 14:4681-8. 10.2147\/IDR.S333985","journal-title":"Infect Drug Resist"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39029","article-title":"Antibiotics associated with Clostridium difficile infection","volume":"15","author":"Rafey A","year":"2023","unstructured":"Rafey A, Jahan S, Farooq U, Akhtar F, Irshad M, Nizamuddin S, Parveen A. Antibiotics associated with Clostridium difficile infection. Cureus. 2023, 15:e39029. 10.7759\/cureus.39029","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5045\/br.2019.54.2.120","article-title":"Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases","volume":"54","author":"Lee-Tsai YL","year":"2019","unstructured":"Lee-Tsai YL, Luna-Santiago R, Demichelis-G\u00f3mez R, et al.. Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases. Blood Res. 2019, 54:120-4. 10.5045\/br.2019.54.2.120","journal-title":"Blood Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2019.1701703","article-title":"Treatment of Clostridioides (Clostridium) difficile infection","volume":"52","author":"Oksi J","year":"2020","unstructured":"Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med. 2020, 52:12-20. 10.1080\/07853890.2019.1701703","journal-title":"Ann Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/329290-clinical-characteristics-and-outcomes-of-clostridioides-difficile-infection-in-cancer-patients-from-a-tertiary-care-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T12:02:13Z","timestamp":1737201733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/329290-clinical-characteristics-and-outcomes-of-clostridioides-difficile-infection-in-cancer-patients-from-a-tertiary-care-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.77616","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,18]]}}}